TY - JOUR
T1 - Effectiveness in switching from antipsychotic polypharmacy to monotherapy in patients with schizophrenia
T2 - A case series
AU - Kamei, Hiroyuki
AU - Yamada, Hanae
AU - Hatano, Masakazu
AU - Hanya, Manako
AU - Yamada, Shigeki
AU - Iwata, Nakao
N1 - Publisher Copyright:
Copyright © 2020, Korean College of Neuropsychopharmacology
PY - 2020
Y1 - 2020
N2 - In Japan, drug therapy for schizophrenia is characterized by high-dose antipsychotic polypharmacy, which is an uncommon approach internationally. In this study, we reduced the number of antipsychotic agents in 5 patients using the Safety Correction of High-dose Antipsychotic Polypharmacy (SCAP) method and conducted a survey regarding treatment satisfaction. The switch from polypharmacy to monotherapy was achieved in all patients. There was no deterioration in psychiatric symptoms, and adverse reactions were reduced. Three of the subjects were satisfied with the decrease in the number of antipsychotic agents and dose-reduction. These results suggest that the SCAP method is a safe and useful method that can be applied in a clinical setting.
AB - In Japan, drug therapy for schizophrenia is characterized by high-dose antipsychotic polypharmacy, which is an uncommon approach internationally. In this study, we reduced the number of antipsychotic agents in 5 patients using the Safety Correction of High-dose Antipsychotic Polypharmacy (SCAP) method and conducted a survey regarding treatment satisfaction. The switch from polypharmacy to monotherapy was achieved in all patients. There was no deterioration in psychiatric symptoms, and adverse reactions were reduced. Three of the subjects were satisfied with the decrease in the number of antipsychotic agents and dose-reduction. These results suggest that the SCAP method is a safe and useful method that can be applied in a clinical setting.
UR - http://www.scopus.com/inward/record.url?scp=85087991007&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087991007&partnerID=8YFLogxK
U2 - 10.9758/CPN.2020.18.1.159
DO - 10.9758/CPN.2020.18.1.159
M3 - Article
AN - SCOPUS:85087991007
SN - 1738-1088
VL - 18
SP - 159
EP - 163
JO - Clinical Psychopharmacology and Neuroscience
JF - Clinical Psychopharmacology and Neuroscience
IS - 1
ER -
